9:00 PM
 | 
Feb 28, 2018
 |  BioCentury  |  Finance

Platform production

RBC play Rubius ramps up for clinical trials with $100M crossover round

Just nine months after closing a $120 million series B round, Rubius Therapeutics Inc. caught the eye of crossover investors who participated in a new $100 million round that will enable the company to further expand its clinical program.

Rubius closed the round on March 1 with participation from Flagship Pioneering and additional undisclosed investors. Executive Chairman David Epstein, who is also an executive partner at Flagship, told BioCentury the round was evenly split between existing investors and new “large U.S. and global mutual funds.”

Rubius has raised $245 million in venture financing since it...

Read the full 459 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >